Schoenermark M P, Mitchell T I, Rutter J L, Reczek P R, Brinckerhoff C E
Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
Ann N Y Acad Sci. 1999 Jun 30;878:466-86. doi: 10.1111/j.1749-6632.1999.tb07703.x.
Cancer mortality usually results from the tumor invading the local environment and metastasizing to vital organs, e.g. liver, lung, and brain. Degradation of the extracellular matrix is, therefore, the sine qua non of tumor cell invasion. this degradation is mediated mainly by MMPs, and thus, inhibition of MMP synthesis is a target for anticancer agents. Tumor cells must traverse both the basement membrane (type IV collagen) and the interstitial stroma (type I collagen). Therefore, we used scanning electron microscopy to examine the invasive behavior of several aggressive tumor cell lines, A2058 melanoma cells, and SCC and FaDu squamous cell carcinomas through these matrices; and we monitored the ability of all-trans retinoic acid and several RAR-specific ligands to block invasion. We demonstrate that several retinoids, which are specific RAR alpha, beta, or gamma agonists/antagonists, selectively inhibited MMP synthesis in the three tumor cell lines. However, there was not a common pattern of MMP inhibition by a particular retinoid. For instance, a RAR alpha antagonist suppressed MMP-1 and MMP-2 synthesis in the melanoma cell line, but not in the FaDu or SCC-25 cells. On the other hand, synthesis of MMP-1 and MMP-9 by the FaDu cells was affected hardly at all, while a RAR gamma antagonist reduced the levels of MMP-2. Only all-trans retinoic acid reduced MMP-1 synthesis in these cells. We postulate that the differences may be related to a differential pattern of RAR expression in each of these cells, and that the RARs expressed by each cell line may not be targets of these RAR specific compounds. All-trans retinoic acid is a pan ligand, binding to all three RARs and, therefore, may modulate gene expression more generally. We conclude that the power of these new ligands lies in their specificity, which can be directed towards modulating expression of certain RARs and, thus, of certain MMPs. By blocking MMP synthesis, retinoids may be effective in cancer therapy by decreasing tumor invasiveness.
癌症死亡率通常是由肿瘤侵袭局部环境并转移至重要器官(如肝脏、肺和脑)所致。因此,细胞外基质的降解是肿瘤细胞侵袭的必要条件。这种降解主要由基质金属蛋白酶(MMPs)介导,因此,抑制MMPs合成是抗癌药物的一个靶点。肿瘤细胞必须穿过基底膜(IV型胶原)和间质基质(I型胶原)。因此,我们使用扫描电子显微镜来检测几种侵袭性肿瘤细胞系、A2058黑色素瘤细胞以及SCC和FaDu鳞状细胞癌通过这些基质的侵袭行为;并且我们监测了全反式维甲酸和几种RAR特异性配体阻断侵袭的能力。我们证明,几种视黄酸,即特异性RARα、β或γ激动剂/拮抗剂,在三种肿瘤细胞系中选择性地抑制MMPs合成。然而,特定视黄酸对MMPs的抑制并没有共同模式。例如,一种RARα拮抗剂抑制黑色素瘤细胞系中MMP-1和MMP-2的合成,但对FaDu或SCC-25细胞无效。另一方面,FaDu细胞中MMP-1和MMP-9的合成几乎未受影响,而一种RARγ拮抗剂降低了MMP-2的水平。只有全反式维甲酸降低了这些细胞中MMP-1的合成。我们推测,这些差异可能与这些细胞中RAR表达的差异模式有关,并且每个细胞系所表达的RAR可能不是这些RAR特异性化合物的靶点。全反式维甲酸是一种泛配体,可与所有三种RAR结合,因此可能更广泛地调节基因表达。我们得出结论,这些新配体的优势在于它们的特异性,可用于调节某些RAR的表达,进而调节某些MMPs的表达。通过阻断MMPs合成,视黄酸可能通过降低肿瘤侵袭性而在癌症治疗中发挥作用。